Danaher Corporation (DHR)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Danaher Corporation.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 1 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 195.00 $ — 41% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 16.9% above the current price.
- Consensus
- Strong Sell
- Analyst Ratings
- 25
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 8.51 | 8.45 – 8.55 | 26,341 | 9.1% | 23 |
| 12/31/2027 | 9.29 | 9.12 – 9.50 | 28,453 | 9.1% | 23 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- 1.91 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 1.47 | 1.90 | 6,538 | 2.10 | 16.60 | 2,019 | 1,503 |
| 2025: Q1 | 1.32 | -8.90 | 5,741 | -0.90 | 16.60 | 1,299 | 1,054 |
| 2025: Q2 | 0.77 | -36.80 | 5,936 | 3.40 | 9.30 | 1,338 | 1,090 |
| 2025: Q3 | 1.27 | 13.40 | 6,053 | 4.40 | 15.00 | 1,662 | 1,370 |
| 2025: Q4 | 1.68 | 14.30 | 6,838 | 4.60 | 17.50 | 2,117 | 1,746 |
| 2026: Q1 | 1.45 | 9.30 | 5,951 | 3.70 | 17.30 | 1,322 | 1,085 |
| 2026: Q2 | 1.23 | 59.70 | 6,265 | 5.50 | 13.90 | 1,534 | 1,265 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 16,882 | 2,987 | 2,554 | 3.65 | 3,522 | 23,003 | 45,295 |
| 2017 | 18,330 | 3,150 | 2,492 | 3.53 | 3,478 | 26,358 | 46,649 |
| 2018 | 17,049 | 3,070 | 2,651 | 3.73 | 4,022 | 28,214 | 47,833 |
| 2019 | 17,911 | 3,362 | 2,557 | 3.52 | 3,952 | 30,271 | 62,082 |
| 2020 | 22,284 | 4,312 | 3,646 | 5.07 | 6,208 | 39,766 | 76,161 |
| 2021 | 29,453 | 8,050 | 6,433 | 8.73 | 8,358 | 45,167 | 83,184 |
| 2022 | 26,643 | 7,536 | 7,209 | 9.78 | 8,519 | 50,082 | 84,350 |
| 2023 | 23,890 | 5,202 | 4,743 | 6.38 | 7,164 | 53,486 | 84,488 |
| 2024 | 23,875 | 5,184 | 3,899 | 5.29 | 6,688 | 49,543 | 77,542 |
| 2025 | 24,568 | 5,137 | 3,614 | 5.08 | 6,416 | 52,534 | 83,464 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Danaher Corporation entwickelt, fertigt und vermarktet professionelle, medizinische, Forschungs- und Industrieprodukte und -dienste in den USA, China und international. Das Unternehmen ist in den Segmenten Biotechnology, Life Sciences und Diagnostics tätig.
| Employees | 58,000 |
|---|---|
| Headquarters | Washington, DC |
| Address | 2200 Pennsylvania Avenue N.W., 20037-1701 Washington, United States |
| Phone | 202 828 0850 |
| Website | danaher.com |
| IPO Date | 5. Jan 1979 |
| ISIN | US2358511028 |
| Stock Split | 1128:1000 on 10/02/2023 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Steven M. Rales | Co-Founder & Chairman | 1951 |
| Rainer M. Blair | President, CEO & Director | 1964 |
| Mitchell P. Rales | Co-Founder & Director | 1957 |
| Jose-Carlos Gutierrez-Ramos Ph.D. | Senior VP & Chief Science Officer | 1962 |
| Matthew R. McGrew | Executive Vice President | 1972 |
| Christopher Paul Riley | Executive VP of Biotechnology Group & CEO of Cytiva | 1974 |
| Julie Sawyer Montgomery | Executive Vice President of Diagnostics Platform | 1973 |
| Matthew E. Gugino C.F.A., CPA | Executive VP & CFO | 1983 |
| Christopher M. Bouda | VP & Chief Accounting Officer | – |
| Martin Stumpe Ph.D. | Chief Technology & AI Officer | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 15. Jul 2026 | Bouda Christopher | VP, Chief Accounting Officer | Other | 60 | 200.79 | 12,047 |
| 15. Jul 2026 | Filler Linda | Director | Other | 1,181 | 200.79 | 237,133 |
| 15. Jul 2026 | Filler Linda | Director | Other | 3,298 | 71.88 | 237,060 |
| 15. Jul 2026 | Zerhouni Elias A. | Director | Other | 1,181 | 200.79 | 237,133 |
| 15. Jul 2026 | Zerhouni Elias A. | Director | Other | 3,298 | 71.88 | 237,060 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.